Similar articles for PMID: 15687359

Year	Number of Results
1975	1
1977	1
1979	1
1981	2
1982	2
1983	3
1992	1
1993	2
1994	3
1995	1
1999	5
2000	2
2001	3
2002	1
2004	3
2005	14
2006	7
2007	10
2008	4
2009	4
2010	3
2011	2
2012	1
2024	0

1

Clinical trial results appear consistent with real-life outcomes in British Columbia.

Susman E. Susman E. J Natl Cancer Inst. 2005 Feb 2;97(3):170. doi: 10.1093/jnci/97.3.170. J Natl Cancer Inst. 2005. PMID: 15687359 No abstract available.

2

Re: Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial.

Kunkler I. Kunkler I. J Natl Cancer Inst. 2005 Aug 3;97(15):1162-3; author reply 1163-4. doi: 10.1093/jnci/dji216. J Natl Cancer Inst. 2005. PMID: 16077078 No abstract available.

3

Bone marrow transplants do not help in breast cancer.

Gottlieb S. Gottlieb S. West J Med. 1999 Jun;170(6):376. West J Med. 1999. PMID: 10443167 Free PMC article. No abstract available.

4

[The 4th large meta-analysis of all trials of the treatment of operable breast cancer: increased survival after a longer follow-up].

van Nes JG, Nortier WR, van de Velde CJ. van Nes JG, et al. Ned Tijdschr Geneeskd. 2005 Sep 3;149(36):1978-80. Ned Tijdschr Geneeskd. 2005. PMID: 16171107 Dutch.

5

Herceptin in early breast cancer: a call for judicious use.

Thorat MA. Thorat MA. Natl Med J India. 2005 Nov-Dec;18(6):315-7. Natl Med J India. 2005. PMID: 16483033 No abstract available.

6

Recent advances in the hormonal treatment of breast cancer.

Boughey JC, Buzdar AU, Hunt KK. Boughey JC, et al. Curr Probl Surg. 2008 Jan;45(1):13-55. doi: 10.1067/j.cpsurg.2007.10.004. Curr Probl Surg. 2008. PMID: 18206436 Review. No abstract available.

7

Better prioritization may speed approval of adjuvant therapies in breast cancer.

Tuma RS. Tuma RS. J Natl Cancer Inst. 2008 Jun 18;100(12):842-4. doi: 10.1093/jnci/djn197. Epub 2008 Jun 10. J Natl Cancer Inst. 2008. PMID: 18544735 No abstract available.

8

Twelve-year mortality results of a randomized trial of 2 versus 5 years of adjuvant tamoxifen for postmenopausal early-stage breast carcinoma patients (SITAM 01).

Alliot C. Alliot C. Cancer. 2006 Jul 1;107(1):215; author reply 215-6. doi: 10.1002/cncr.21960. Cancer. 2006. PMID: 16691577 Free article. No abstract available.

9

Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system.

Hudis CA, Barlow WE, Costantino JP, Gray RJ, Pritchard KI, Chapman JA, Sparano JA, Hunsberger S, Enos RA, Gelber RD, Zujewski JA. Hudis CA, et al. J Clin Oncol. 2007 May 20;25(15):2127-32. doi: 10.1200/JCO.2006.10.3523. J Clin Oncol. 2007. PMID: 17513820

10

Influence of timing of initiation of adjuvant chemotherapy over survival in breast cancer: a negative outcome study by the Spanish Breast Cancer Research Group (GEICAM).

Jara Sánchez C, Ruiz A, Martín M, Antón A, Munárriz B, Plazaola A, Schneider J, Martínez del Prado P, Alba E, Fernández-Aramburo A. Jara Sánchez C, et al. Breast Cancer Res Treat. 2007 Jan;101(2):215-23. doi: 10.1007/s10549-006-9282-0. Epub 2006 Jul 6. Breast Cancer Res Treat. 2007. PMID: 16823507

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

73 results

Results by year